Expert Discusses Celsion’s Ovarian Cancer Immunotherapy GEN-1; Phase 1/2 Trial Still Enrolling

Expert Discusses Celsion’s Ovarian Cancer Immunotherapy GEN-1; Phase 1/2 Trial Still Enrolling
The ovarian cancer immunotherapy candidate GEN-1, which is being tested in a Phase 1/2 clinical trial in newly diagnosed patients with advanced disease, was the focus of a recent call with a gynecologic oncology expert. The OVATION 2 trial (NCT03393884) is enrolling at 34 sites across the U.S. It will test the safety and effectiveness of GEN-1 in up to 130 patients with newly diagnosed advanced or metastatic ovarian (stage III/IV), fallopian tube, or primary peritoneal cancer. GEN-1, developed by Celsion Corporation, is a nanoparticle containing a vector with the DNA sequence for the pro-inflammatory protein interleukin (IL)-12. Delivery to the tumor cells is followed by release of IL-12, which induces anti-cancer immune responses by activating immune T-cells and natural killer (NK) cell proliferation. The call about ovarian cancer treatments and emerging opportunities was
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *